 EMERYVILLE, Calif., Dec. 23, 2020 GLOBE NEWSWIRE -- Gritstone Oncology, Inc. Nasdaq: GRTS, a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that it has executed a securities purchase agreement to raise gross proceeds of 110 million resulting from the sale of shares of its common stock andor pre-funded warrants through a private investment in public equity PIPE financing at a price per share of 3.34. The financing was led by certain existing and new investors, Redmile Group, Avidity Partners and EcoR1 Capital. 